2020 Acquired array (CLL and MDS)

Scheme description
DNA analysis of haematological cases (CLL and myeloid) for the detection of recurrent and non-recurrent abnormalities. Array and NGS can be undertaken for copy number loss and gain.
Disorders/Gene target(s)
Chronic Lymphocytic Leukaemia (CLL)
Myelodysplastic syndrome (MDS)
Clinical cases
Two
Testing/analysis
Whole genome copy number changes and structural rearrangements.
Sample type
DNA in TE buffer
Techniques
Array, NGS, Any method
Assessment
Submit a clinical report to include:
● Analysis of results
● Interpretation of the result
● Clerical accuracy
Performance criteria are applied.
Eligibility
All laboratories worldwide
Languages
English, German, Italian, Spanish, French
ISO1743 Accredited EQA
No
EQA timeline
Sample dispatchApril 2020
Testing period5 weeks
Assessment resultsJuly 2020
Final Summary reportOctober 2020
Other information
Fee
£375.00
GenQA code
2020ACQAR
« Return to EQA scheme list
Go to top